USFDA issues six observations post inspection of Biocon s Malaysian arm manufacturing facility businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.
KUALA LUMPUR (Dec 29): Duopharma Biotech Bhd said the government has extended the agreement for the supply and delivery of human insulin products by one year, from Dec 2, 2020 to Dec 1, 2021, with an additional contract value of RM19.625 million.
In a filing with Bursa Malaysia today, Duopharma Biotech said the agreement was between the government, Biocon Sdn Bhd as the manufacturer, and Duopharma Marketing Sdn Bhd (DMktg), a wholly-owned subsidiary of Duopharma Biotech, as Biocon’s authorised distributor/reseller.
It said following this second additional contract value, the total contract value has been increased to RM410.725 million from RM300.04 million under the original agreement.